Last reviewed · How we verify
NCT06166082
Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression
NA trial testing Active iTBS-DLPFC in Treatment Resistant Depression in 130 participants. Status unknown.
31 July 2024
Quick facts
| Lead sponsor | Changping Laboratory |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 22 December 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 5 locations across China |
Drugs / interventions tested
- Active iTBS-DLPFC
- Sham iTBS-DLPFC
Conditions studied
- Treatment Resistant Depression — all drugs for Treatment Resistant Depression →
Sponsor
Changping Laboratory
Who can join
Adults 22 to 65, any sex, with Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, randomized, double-blind, and sham-controlled trial using the identical protocol as the SNT to replicate the antidepressant efficacy of SNT for TRD. Patients will be recruited and randomly assigned (1:1 ratio) to receive active or sham groups from 5 hospitals in China. The interventions will last for 5 days and both groups will be followed up for 8 weeks on the same time schedules. During the intervention and at least the first 4 weeks of post-treatment, participants will keep a stable antidepressant regimen. The individualized SNT target in the left dorsolateral prefrontal cortex (DLPFC) will be generated from 30 minutes of resting-state functional MRI collected at baseline.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Longer scans boost prediction and cut costs in brain-wide association studies.
Ooi LQR, Orban C, Zhang S, Nichols TE, et al · · 2025 · cited 33× · PMID 40670782 · DOI 10.1038/s41586-025-09250-1
Verify or expand the search:
- PubMed search for NCT06166082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active iTBS-DLPFC
Trials testing the same drug.
- NCT04076124 — Brain-derived Neurotrophic Factor and the Antidepressant Efficacy of Brain Stimulation · NA · unknown
Other recruiting trials for Treatment Resistant Depression
Currently open trials in the same condition.
- NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
- NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
- NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
- NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting
Other Changping Laboratory trials
Trials by the same sponsor.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
- NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
- NCT05999318 — pBFS-guided cTBS Over the Superior Temporal Gyrus for Aphasia After Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06166082 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
- Last refreshed: 6 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06166082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing